Just an abstract from the Presentation at the 2014 Scientific Session. The abstract points to a 40% reduction in CAD with the onset of BHRT (Estradiol and progesterone topical) within 6 years of menopause compared to women 10 years post-menopause. This points to timing as a critical component of BHRT in women and CAD.
This study shows that DHT is a good alternative androgen to Testosterone. It was shown to have no positive/negative effect on the prostate. The negative of this study was found to be bone loss from supra physiologic DHT. The point there is to keep hormone replacement physiologic, as one should with all BHRT.
oral estrogen is a bad choice as it relates to BHRT or HRT for that matter. Compared to transdermal estrogen, oral estrogen through increasing TBG and slowed liver metabolism results in decreased thyroid hormone production.
Yale study finds estrogen therapy in improves health in women ages 50-59. The problems with hormone therapy is synthetics and overdosing. The problem with the WHI was they used medroxy progesterone acetate--a synthetic progestin. That is not progesterone. This study estimated that 91,000 + died due to the uneducated view that estrogen HRT is dangerous. What is dangerous is leaving the HRT and BHRT recommendations to those with conflicts of interest and a lack of knowledge of the science.
Bioidentical progesterone used in IVF. This is not new, the SQ administration is. So, physicians cry against BHRT, yet bioidentical progesterone has been used for years in the treatment of infertility.
study of 80,377 postmenopausal women found no increase/decrease in breast cancer in women on estradiol and progesterone (RR 1.0). However, estradiol and provera (synthetic progestin) found a 69% increased breast cancer risk (RR 1.69).
"...in the subgroup of women starting HRT between ages 50 and 59 or less than 10 years after menopause...reduction of overall mortality and coronary artery disease."